solid tumours

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

Oncology

How today’s biotechs are helping us Stand Up To Cancer

In recognition of Stand Up To Cancer Day, a look at next-generation treatments that are on the verge of making it into clinical practice.

Oncology

Bridging the innovation gap: Scalable cell therapies, adapti...

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

News

Akeso and CStone secure China clearances for next-generation...

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

News

Akiram, ITM sign Lutetium-177 supply agreement

Akiram & ITM sign supply agreement for Lutetium-177 to support development of targeted antibody-radionuclide conjugate AKIR001 in solid tumours.

In vivo CAR-T can solve the delivery problem – but solid tum...

Australia, CAR-T therapy, and solid tumours

How today’s biotechs are helping us Stand Up To Cancer

Bridging the innovation gap: Scalable cell therapies, adapti...

Akeso and CStone secure China clearances for next-generation...

Akiram, ITM sign Lutetium-177 supply agreement

Iambic prices its IPO, seeking to raise up to $160m

Discover a new era of healthcare panel engagement: Grounded ...

solid tumours

Editor's Picks